A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Amgen
Enrollment	88 participants

Key Eligibility Criteria

Inclusion (14)

- Participant has provided informed consent before initiation of any study-specific activities/procedures.
- Male or female aged 18 to 55 years (Part A).
- Female participants must be of non-childbearing potential.
- Body mass index (BMI) between 18 and 30 kg/m\^2, inclusive, at screening.
- The participant has adequate venous access and can receive intravenous (IV) therapy.

... and 9 more (see full listing online)

Exclusion (13)

- Malignant condition in the past 12 months or major surgery within 8 weeks or plans to have an elective surgery from screening through end of study.
- Active liver or kidney disfunction at screening.
- Positive test for hepatitis B/C or Human immunodeficiency virus (HIV) serology at screening.
- Glycated hemoglobin (HbA1c) \> 6.5% and/or fasting glucose levels\> 126 mg/dL (\> 7 mmol/L) at screening.
- Use of any steroid (IV, oral, steroid eye drops) within 3 weeks prior to the first dose. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids and steroids used to treat injection related reactions or short course of steroid for asthma control.

... and 8 more (see full listing online)

Locations (29 total)

Applied Research Center of Arkansas, Little Rock, Arkansas, United States
Levenson Eye Associates, Jacksonville, Florida, United States
Ilumina Medical Research, Kissimmee, Florida, United States
... and 26 more locations